[{"id":"c537cdaa-ab2e-4d12-a7a6-739ded23e41a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02285816","created_at":"2021-01-18T10:46:19.368Z","updated_at":"2024-07-02T16:35:17.712Z","phase":"Phase 1/2","brief_title":"MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours","source_id_and_acronym":"NCT02285816","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" PD-L1 • MAGEA3","pipe":" | ","alterations":" EGFR mutation • ALK mutation","tags":["PD-L1 • MAGEA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Marabex (MAGE-A3 vaccine)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 01/22/2015","start_date":" 01/22/2015","primary_txt":" Primary completion: 09/19/2019","primary_completion_date":" 09/19/2019","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-02-26"},{"id":"a22bdba7-a048-4ead-8b32-f496954c7c9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02111850","created_at":"2021-01-18T09:45:59.926Z","updated_at":"2024-07-02T16:36:14.557Z","phase":"Phase 1/2","brief_title":"T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive","source_id_and_acronym":"NCT02111850","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4 • GAPDH • MAGEA3","pipe":"","alterations":" ","tags":["CD4 • GAPDH • MAGEA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • MAGE A3 TCR • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 02/07/2014","start_date":" 02/07/2014","primary_txt":" Primary completion: 03/24/2021","primary_completion_date":" 03/24/2021","study_txt":" Completion: 03/24/2021","study_completion_date":" 03/24/2021","last_update_posted":"2022-03-29"},{"id":"27ec7915-3e37-4d12-83f7-0afc1f629fe0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02873819","created_at":"2021-04-27T08:57:21.330Z","updated_at":"2024-07-02T16:36:15.914Z","phase":"Phase 2","brief_title":"Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity","source_id_and_acronym":"NCT02873819","lead_sponsor":"Gliknik Inc.","biomarkers":" MAGEA3","pipe":"","alterations":" ","tags":["MAGEA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • cyclophosphamide • Hiltonol (poly-ICLC) • Leukine (sargramostim) • biropepimut-S (GL-0817) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 03/30/2017","start_date":" 03/30/2017","primary_txt":" Primary completion: 05/17/2021","primary_completion_date":" 05/17/2021","study_txt":" Completion: 05/25/2021","study_completion_date":" 05/25/2021","last_update_posted":"2022-03-08"},{"id":"9a08485b-b8fa-4035-b77f-9d260c28ce59","acronym":"","url":"https://clinicaltrials.gov/study/NCT00896480","created_at":"2021-01-18T03:26:13.770Z","updated_at":"2024-07-02T16:36:32.176Z","phase":"Phase 2","brief_title":"Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma","source_id_and_acronym":"NCT00896480","lead_sponsor":"GlaxoSmithKline","biomarkers":" ALK • CD8 • IFNG • TNFA • CD4 • MAGEA3","pipe":"","alterations":" ","tags":["ALK • CD8 • IFNG • TNFA • CD4 • MAGEA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zumagev (astuprotimut-R)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 05/19/2009","start_date":" 05/19/2009","primary_txt":" Primary completion: 11/03/2014","primary_completion_date":" 11/03/2014","study_txt":" Completion: 11/03/2014","study_completion_date":" 11/03/2014","last_update_posted":"2021-04-08"},{"id":"0ed7372c-197f-41fe-bce0-6db0f30c2530","acronym":"Pelican","url":"https://clinicaltrials.gov/study/NCT03773744","created_at":"2021-04-27T08:58:31.456Z","updated_at":"2024-07-02T16:36:32.334Z","phase":"Phase 1b","brief_title":"MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma","source_id_and_acronym":"NCT03773744 - Pelican","lead_sponsor":"Turnstone Biologics, Corp.","biomarkers":" MAGEA3","pipe":"","alterations":" ","tags":["MAGEA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • Marabex (MAGE-A3 vaccine) • cyclophosphamide intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/15/2020","start_date":" 02/15/2020","primary_txt":" Primary completion: 10/30/2020","primary_completion_date":" 10/30/2020","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2021-04-06"},{"id":"93524cf9-a66e-4507-b9c9-063ac316366a","acronym":"PREDICT","url":"https://clinicaltrials.gov/study/NCT00942162","created_at":"2021-01-18T03:39:27.818Z","updated_at":"2024-07-02T16:36:37.713Z","phase":"Phase 2","brief_title":"A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma","source_id_and_acronym":"NCT00942162 - PREDICT","lead_sponsor":"GlaxoSmithKline","biomarkers":" ALK • MAGEA3","pipe":"","alterations":" ","tags":["ALK • MAGEA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zumagev (astuprotimut-R)"],"overall_status":"Completed","enrollment":" Enrollment 125","initiation":"Initiation: 08/14/2009","start_date":" 08/14/2009","primary_txt":" Primary completion: 06/27/2012","primary_completion_date":" 06/27/2012","study_txt":" Completion: 04/01/2015","study_completion_date":" 04/01/2015","last_update_posted":"2020-12-08"},{"id":"f300a0e2-8789-4980-a047-3b4280d68a5d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02879760","created_at":"2021-01-18T14:08:14.143Z","updated_at":"2024-07-02T16:36:40.338Z","phase":"Phase 1/2","brief_title":"Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients","source_id_and_acronym":"NCT02879760","lead_sponsor":"Turnstone Biologics, Corp.","biomarkers":" ALK • MAGEA3","pipe":" | ","alterations":" EGFR mutation • ALK translocation","tags":["ALK • MAGEA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Marabex (MAGE-A3 vaccine)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 03/08/2017","start_date":" 03/08/2017","primary_txt":" Primary completion: 02/15/2020","primary_completion_date":" 02/15/2020","study_txt":" Completion: 05/24/2020","study_completion_date":" 05/24/2020","last_update_posted":"2020-10-06"},{"id":"e3c3481a-4a24-4334-a6f6-ce5a4ce224dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01266603","created_at":"2021-01-18T05:07:17.231Z","updated_at":"2025-02-25T13:16:31.595Z","phase":"Phase 2","brief_title":"High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI","source_id_and_acronym":"NCT01266603","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MAGEA3","pipe":"","alterations":" ","tags":["MAGEA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Proleukin (aldesleukin) • Promune (agatolimod) • Zumagev (astuprotimut-R)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 02/22/2011","start_date":" 02/22/2011","primary_txt":" Primary completion: 11/01/2018","primary_completion_date":" 11/01/2018","study_txt":" Completion: 11/01/2018","study_completion_date":" 11/01/2018","last_update_posted":"2020-02-19"},{"id":"6f649007-b4d2-4b1d-968c-db29ab2d4c39","acronym":"","url":"https://clinicaltrials.gov/study/NCT00290355","created_at":"2021-01-18T00:59:20.464Z","updated_at":"2024-07-02T16:36:51.968Z","phase":"Phase 2b","brief_title":"Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery","source_id_and_acronym":"NCT00290355","lead_sponsor":"GlaxoSmithKline","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zumagev (astuprotimut-R)"],"overall_status":"Completed","enrollment":" Enrollment 182","initiation":"Initiation: 05/28/2002","start_date":" 05/28/2002","primary_txt":" Primary completion: 07/19/2011","primary_completion_date":" 07/19/2011","study_txt":" Completion: 07/19/2011","study_completion_date":" 07/19/2011","last_update_posted":"2020-01-02"}]